PhRMA Pleased By HRSA's Steps To Limit Patients Eligible For 340B, But Urges More Controls

The brand-name pharmaceutical industry is pleased with certain changes the Health Resources and Services Administration made that some say could restrict the scope of patients eligible to be treated with discounted drugs under the 340B program, but drug makers say HRSA's newly issued guidance doesn't go far enough to resolve their concerns about 340B program integrity. “A first look at the guidance indicates both positive signs that HRSA is taking steps to curb abuses of the program as well as...